Dengue Vaccine Sales Increase 259%

According to the World Health Organization (WHO), more than 13 million dengue cases were reported in 2024, the highest number on record.

According to recent data, the dengue global outbreak has continued in 2025.

To reduce the health impact of this mosquito-transmitted viral infection, more people than ever were immunized with a dengue vaccine.

Announced today by Japan-based Takeda, the only WHO-listed dengue vaccine QDENGA®'s Q4 FY2024 (April 2024-March 2025), Revenue was JPY 35.6 billion ($247,746,985), an increase of 259%.

QDENGA® (TAK-003) is a tetravalent, two-dose vaccine approved for preventing dengue fever and/or Severe Dengue caused by any of the four serotypes of the dengue virus. 

As of May 8, 2025, QDENGA was authorized in about 40 countries, with authorizations pending in the Philippines and India. 

Unfortunately, no dengue vaccine is available in the United States, even in Puerto Rico, were dengue has become endemic.